【港股异动 | CRO概念股多数走高药明康德(02359.HK)上半年业绩符合预期在手订单首超400亿】智通财经APP获悉，CRO概念股多数走高，截至发稿，药明康德(02359.

智通财经07-30

【港股异动 | CRO概念股多数走高药明康德(02359.HK)上半年业绩符合预期在手订单首超400亿】智通财经APP获悉，CRO概念股多数走高，截至发稿，药明康德(02359.HK)涨6.26%，报30.55港元；维亚生物(01873.HK)涨4%，报0.52港元；康龙化成(03759.HK)涨3.5%，报9.16港元；凯莱英(06821.HK)涨2.73%，报45.1港元；药明生物(...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2455629104?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-30 10:37","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2455629104","market":"hk","top_or_hot":-1,"title":"【港股异动 | CRO概念股多数走高 药明康德(02359.HK)上半年业绩符合预期 在手订单首超400亿】智通财经APP获悉，CRO概念股多数走高，截至发稿，药明康德(02359.","media":"智通财经","content":"<div>\n<p>【港股异动 | CRO概念股多数走高 药明康德(02359.HK)上半年业绩符合预期 在手订单首超400亿】智通财经APP获悉，CRO概念股多数走高，截至发稿，药明康德(02359.HK)涨6.26%，报30.55港元；维亚生物(01873.HK)涨4%，报0.52港元；康龙化成(03759.HK)涨3.5%，报9.16港元；凯莱英(06821.HK)涨2.73%，报45.1港元；药明生物(...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7x24快讯</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7x24快讯\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-30 10:37 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=ganggu><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【港股异动 | CRO概念股多数走高 药明康德(02359.HK)上半年业绩符合预期 在手订单首超400亿】智通财经APP获悉，CRO概念股多数走高，截至发稿，药明康德(02359.HK)涨6.26%，报30.55港元；维亚生物(01873.HK)涨4%，报0.52港元；康龙化成(03759.HK)涨3.5%，报9.16港元；凯莱英(06821.HK)涨2.73%，报45.1港元；药明生物(...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0516422366.SGD","symbol_name":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2455629104","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2455629104","pubTimestamp":1722307038,"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【港股异动 | CRO概念股多数走高 药明康德(02359.HK)上半年业绩符合预期 在手订单首超400亿】智通财经APP获悉，CRO概念股多数走高，截至发稿，药明康德(02359.HK)涨6.26%","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300759":"康龙化成","603259":"药明康德","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU1046422090.SGD":"Fidelity Pacific A-SGD","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","BK1141":"生命科学工具和服务","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","02269":"药明生物","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1997245177.USD":"安联神洲A股基金","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU1720050803.USD":"安联全方位中国股票基金","03759":"康龙化成","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","002821":"凯莱英","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","BK1583":"高瓴概念","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","BK1610":"ETF&股票定投概念","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","BK1589":"北水核心资产","01873":"维亚生物","02359":"药明康德","LU0823426480.USD":"法巴中国股票经典Dis","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","06821":"凯莱英","LU0359201612.USD":"贝莱德中国基金A2","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC"},"translate_title":"[Hong Kong stocks changed, most CRO concept stocks rose, WuXi AppTec (02359. HK) 's first half performance was in line with expectations, and orders on hand exceeded 40 billion for the first time] Zhitong Finance AP","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300759":1,"603259":1,"01873":1,"02269":1,"02359":1,"03759":1,"06821":1,"002821":1},"content_text":"【港股异动 | CRO概念股多数走高 药明康德(02359.HK)上半年业绩符合预期 在手订单首超400亿】智通财经APP获悉，CRO概念股多数走高，截至发稿，药明康德(02359.HK)涨6.26%，报30.55港元；维亚生物(01873.HK)涨4%，报0.52港元；康龙化成(03759.HK)涨3.5%，报9.16港元；凯莱英(06821.HK)涨2.73%，报45.1港元；药明生物(02269.HK)涨1.89%，报10.76港元。","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2455629104"}

【港股异动 | CRO概念股多数走高 药明康德(02359.HK)上半年业绩符合预期 在手订单首超400亿】智通财经APP获悉，CRO概念股多数走高，截至发稿，药明康德(02359.

精彩评论

【港股异动 | CRO概念股多数走高药明康德(02359.HK)上半年业绩符合预期在手订单首超400亿】智通财经APP获悉，CRO概念股多数走高，截至发稿，药明康德(02359.